Literature DB >> 26856667

The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia.

Lorraine B Ware1, Jason D Christie2,3, Joshua M Diamond2, Mary K Porteous2, L Jackson Roberts4, Nancy Wickersham5, Melanie Rushefski2, Steven M Kawut2,3,6, Rupal J Shah7, Edward Cantu8, David J Lederer9, Shampa Chatterjee10, Vibha N Lama11, Sangeeta Bhorade12, Maria Crespo13, John McDyer13, Keith Wille14, Jonathan Orens15, Ann Weinacker16, Selim Arcasoy9, Pali D Shah15, David S Wilkes17, Chadi Hage17, Scott M Palmer18, Laurie Snyder18, Carolyn S Calfee7,19.   

Abstract

BACKGROUND: Donor smoking history and higher fraction of inspired oxygen (FIO2) at reperfusion are associated with primary graft dysfunction (PGD) after lung transplantation. We hypothesized that oxidative injury biomarkers would be elevated in PGD, with higher levels associated with donor exposure to cigarette smoke and recipient hyperoxia at reperfusion.
METHODS: We performed a nested case-control study of 72 lung transplant recipients from the Lung Transplant Outcomes Group cohort. Using mass spectroscopy, F2-isoprostanes and isofurans were measured in plasma collected after transplantation. Cases were defined in 2 ways: grade 3 PGD present at day 2 or day 3 after reperfusion (severe PGD) or any grade 3 PGD (any PGD).
RESULTS: There were 31 severe PGD cases with 41 controls and 35 any PGD cases with 37 controls. Plasma F2-isoprostane levels were higher in severe PGD cases compared with controls (28.6 pg/ml vs 19.8 pg/ml, p = 0.03). Plasma F2-isoprostane levels were higher in severe PGD cases compared with controls (29.6 pg/ml vs 19.0 pg/ml, p = 0.03) among patients reperfused with FIO2 >40%. Among recipients of lungs from donors with smoke exposure, plasma F2-isoprostane (38.2 pg/ml vs 22.5 pg/ml, p = 0.046) and isofuran (66.9 pg/ml vs 34.6 pg/ml, p = 0.046) levels were higher in severe PGD compared with control subjects.
CONCLUSIONS: Plasma levels of lipid peroxidation products are higher in patients with severe PGD, in recipients of lungs from donors with smoke exposure, and in recipients exposed to higher Fio2 at reperfusion. Oxidative injury is an important mechanism of PGD and may be magnified by donor exposure to cigarette smoke and hyperoxia at reperfusion.
Copyright © 2016 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  F2-isoprostane; ischemia reperfusion; isofuran; lipid peroxidation; lung transplantation; primary graft dysfunction

Mesh:

Substances:

Year:  2016        PMID: 26856667      PMCID: PMC4821817          DOI: 10.1016/j.healun.2015.12.012

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  46 in total

1.  Objective Estimates Improve Risk Stratification for Primary Graft Dysfunction after Lung Transplantation.

Authors:  R J Shah; J M Diamond; E Cantu; J Flesch; J C Lee; D J Lederer; V N Lama; J Orens; A Weinacker; D S Wilkes; D Roe; S Bhorade; K M Wille; L B Ware; S M Palmer; M Crespo; E Demissie; J Sonnet; A Shah; S M Kawut; S L Bellamy; A R Localio; J D Christie
Journal:  Am J Transplant       Date:  2015-04-15       Impact factor: 8.086

2.  Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part III: donor-related risk factors and markers.

Authors:  Marc de Perrot; Robert S Bonser; John Dark; Rosemary F Kelly; David McGiffin; Rebecca Menza; Octavio Pajaro; Stephan Schueler; Geert M Verleden
Journal:  J Heart Lung Transplant       Date:  2005-08-08       Impact factor: 10.247

3.  Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part I: introduction and methods.

Authors:  Jason D Christie; Dirk Van Raemdonck; Marc de Perrot; Mark Barr; Shaf Keshavjee; Selim Arcasoy; Jonathan Orens
Journal:  J Heart Lung Transplant       Date:  2005-10       Impact factor: 10.247

4.  Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part IV: recipient-related risk factors and markers.

Authors:  Mark L Barr; Steven M Kawut; Timothy P Whelan; Reda Girgis; Heidi Böttcher; Joshua Sonett; Wickii Vigneswaran; David M Follette; Paul A Corris
Journal:  J Heart Lung Transplant       Date:  2005-07-27       Impact factor: 10.247

5.  Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation.

Authors:  Jason D Christie; Martin Carby; Remzi Bag; Paul Corris; Marshall Hertz; David Weill
Journal:  J Heart Lung Transplant       Date:  2005-06-04       Impact factor: 10.247

6.  Donor smoking is associated with pulmonary edema, inflammation and epithelial dysfunction in ex vivo human donor lungs.

Authors:  L B Ware; J W Lee; N Wickersham; J Nguyen; M A Matthay; C S Calfee
Journal:  Am J Transplant       Date:  2014-08-21       Impact factor: 8.086

Review 7.  Effects of hyperoxic exposure on signal transduction pathways in the lung.

Authors:  Andrea Porzionato; Maria Martina Sfriso; Andrea Mazzatenta; Veronica Macchi; Raffaele De Caro; Camillo Di Giulio
Journal:  Respir Physiol Neurobiol       Date:  2014-12-06       Impact factor: 1.931

8.  Mice deficient in the gene for cytochrome P450 (CYP)1A1 are more susceptible than wild-type to hyperoxic lung injury: evidence for protective role of CYP1A1 against oxidative stress.

Authors:  Krithika Lingappan; Weiwu Jiang; Lihua Wang; Gangduo Wang; Xanthi I Couroucli; Binoy Shivanna; Stephen E Welty; Roberto Barrios; M Firoze Khan; Daniel W Nebert; L Jackson Roberts; Bhagavatula Moorthy
Journal:  Toxicol Sci       Date:  2014-06-03       Impact factor: 4.849

9.  Flaxseed modulates inflammatory and oxidative stress biomarkers in cystic fibrosis: a pilot study.

Authors:  Jason B Turowski; Ralph A Pietrofesa; John A Lawson; Melpo Christofidou-Solomidou; Denis Hadjiliadis
Journal:  BMC Complement Altern Med       Date:  2015-05-13       Impact factor: 3.659

10.  Protective Effects of Valproic Acid, a Histone Deacetylase Inhibitor, against Hyperoxic Lung Injury in a Neonatal Rat Model.

Authors:  Merih Cetinkaya; Mehmet Cansev; Ferhat Cekmez; Cuneyt Tayman; Fuat Emre Canpolat; Ilker Mustafa Kafa; Esra Orenlili Yaylagul; Boris W Kramer; Serdar Umit Sarici
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

View more
  9 in total

1.  Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertension.

Authors:  Mary K Porteous; James C Lee; David J Lederer; Scott M Palmer; Edward Cantu; Rupal J Shah; Scarlett L Bellamy; Vibha N Lama; Sangeeta M Bhorade; Maria M Crespo; John F McDyer; Keith M Wille; A Russell Localio; Jonathan B Orens; Pali D Shah; Ann B Weinacker; Selim Arcasoy; David S Wilkes; Lorraine B Ware; Jason D Christie; Steven M Kawut; Joshua M Diamond
Journal:  Ann Am Thorac Soc       Date:  2017-10

2.  Aryl-Hydrocarbon Receptor Repressor Gene in Primary Graft Dysfunction after Lung Transplantation.

Authors:  Michaela R Anderson; Ethan A Edwin; Joshua M Diamond; Anthony Ferrante; Joshua Sonett; Frank D'Ovidio; Selim Arcasoy; Edward Cantu; Jason D Christie; David J Lederer
Journal:  Am J Respir Cell Mol Biol       Date:  2019-08       Impact factor: 6.914

Review 3.  The Future of Lung Transplantation.

Authors:  Katherine A Young; Daniel F Dilling
Journal:  Chest       Date:  2018-08-29       Impact factor: 9.410

4.  Cell-free hemoglobin promotes primary graft dysfunction through oxidative lung endothelial injury.

Authors:  Ciara M Shaver; Nancy Wickersham; J Brennan McNeil; Hiromasa Nagata; Adam Miller; Stuart R Landstreet; Jamie L Kuck; Joshua M Diamond; David J Lederer; Steven M Kawut; Scott M Palmer; Keith M Wille; Ann Weinacker; Vibha N Lama; Maria M Crespo; Jonathan B Orens; Pali D Shah; Chadi A Hage; Edward Cantu; Mary K Porteous; Gundeep Dhillon; John McDyer; Julie A Bastarache; Jason D Christie; Lorraine B Ware
Journal:  JCI Insight       Date:  2018-01-25

5.  Adipose tissue quantification and primary graft dysfunction after lung transplantation: The Lung Transplant Body Composition study.

Authors:  Michaela R Anderson; Jayaram K Udupa; Ethan Edwin; Joshua M Diamond; Jonathan P Singer; Jasleen Kukreja; Steven R Hays; John R Greenland; Anthony Ferrante; Matthew Lippel; Tatiana Blue; Amika McBurnie; Michelle Oyster; Laurel Kalman; Melanie Rushefski; Caiyun Wu; Gargi Pednekar; Wen Liu; Selim Arcasoy; Joshua Sonett; Frank D'Ovidio; Matthew Bacchetta; John D Newell; Drew Torigian; Edward Cantu; Donna L Farber; Jon T Giles; Yubing Tong; Scott Palmer; Lorraine B Ware; Wayne W Hancock; Jason D Christie; David J Lederer
Journal:  J Heart Lung Transplant       Date:  2019-08-10       Impact factor: 10.247

Review 6.  Primary graft dysfunction: pathophysiology to guide new preventive therapies.

Authors:  Ciara M Shaver; Lorraine B Ware
Journal:  Expert Rev Respir Med       Date:  2017-01-20       Impact factor: 3.772

7.  Risk of primary graft dysfunction following lung transplantation in selected adults with connective tissue disease-associated interstitial lung disease.

Authors:  Jake G Natalini; Joshua M Diamond; Mary K Porteous; David J Lederer; Keith M Wille; Ann B Weinacker; Jonathan B Orens; Pali D Shah; Vibha N Lama; John F McDyer; Laurie D Snyder; Chadi A Hage; Jonathan P Singer; Lorraine B Ware; Edward Cantu; Michelle Oyster; Laurel Kalman; Jason D Christie; Steven M Kawut; Elana J Bernstein
Journal:  J Heart Lung Transplant       Date:  2021-01-23       Impact factor: 10.247

Review 8.  Lipid (per) oxidation in mitochondria: an emerging target in the ageing process?

Authors:  O S Ademowo; H K I Dias; D G A Burton; H R Griffiths
Journal:  Biogerontology       Date:  2017-05-24       Impact factor: 4.277

9.  Volatile organic compound profiling to explore primary graft dysfunction after lung transplantation.

Authors:  Pierre-Hugues Stefanuto; Rosalba Romano; Christiaan A Rees; Mavra Nasir; Louit Thakuria; Andre Simon; Anna K Reed; Nandor Marczin; Jane E Hill
Journal:  Sci Rep       Date:  2022-02-08       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.